Stocktoria
CG Oncology, Inc. CGON
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-01-25
Chart by TradingView
2/9
Piotroski F — financial health
23.13
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Revenue | $4.0M | $1.1M | $204,000 |
| Operating income | -$190.8M | -$114.7M | -$55.4M |
| Net income | -$161.0M | -$88.0M | -$48.6M |
| Operating cash flow | -$132.3M | -$78.7M | -$45.7M |
| Free cash flow | -$132.5M | -$78.9M | — |
| Total assets | $791.6M | $754.8M | $199.3M |
| Total liabilities | $39.0M | $21.4M | $14.5M |
| Shareholders' equity | $752.6M | $733.4M | -$123.1M |
| Ratios | |||
| Operating margin | -4722.1% | -10067.3% | -27180.9% |
| Net margin | -3985.0% | -7729.5% | -23827.0% |
| FCF margin | -3279.2% | -6931.3% | — |
| Return on assets | -20.3% | -11.7% | -24.4% |
| Return on equity | -21.4% | -12.0% | 39.5% |
| Debt / equity | 0.00× | 0.00× | — |
| Current ratio | 24.63 | 35.30 | 13.62 |
| Revenue growth | 254.7% | 458.3% | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 425,292 | $28.8M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 23.13 (safe)
- Working capital / assets 0.92
- Retained earnings / assets -0.479
- EBIT / assets -0.241
- Equity / liabilities 19.302
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001991792 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.